Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$10 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-6.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2.7
Industry P/E
--
EV/EBITDA
-0.4
Div. Yield
0 %
Debt to Equity
--
Book Value
$13119.9
EPS
$-15804.7
Face value
--
Shares outstanding
1,616,179
CFO
$-36.11 Mln
EBITDA
$-0.94 Mln
Net Profit
$11.02 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Quoin Pharmaceuticals (QNRX)
| -51.4 | -16.1 | -51.4 | -5.2 | -85.7 | -90.2 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Quoin Pharmaceuticals (QNRX)
| -36.6 | -86.5 | -71.2 | -93.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Quoin Pharmaceuticals (QNRX)
|
7.0 | 10.2 | 0.0 | -15,804.7 | -- | -240.8 | -- | 2.7 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 229.3 | 13,405.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 7.3 | 6,847.2 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical... lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Netherton Syndrome; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc. Address: 42127 Pleasant Forest Court, Ashburn, VA, United States, 20148-7349 Read more
Co-Founder, CEO & Chairman
Dr. Michael Myers Ph.D.
Co-Founder, CEO & Chairman
Dr. Michael Myers Ph.D.
Headquarters
Ashburn, VA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Quoin Pharmaceuticals Ltd (QNRX) is $7.02 (NASDAQ) as of 02-Apr-2026 16:00 EDT. Quoin Pharmaceuticals Ltd (QNRX) has given a return of -85.69% in the last 3 years.
Since, TTM earnings of Quoin Pharmaceuticals Ltd (QNRX) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.00
|
0.00
|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
The 52-week high and low of Quoin Pharmaceuticals Ltd (QNRX) are Rs 41.80 and Rs 5.05 as of 03-Apr-2026.
Quoin Pharmaceuticals Ltd (QNRX) has a market capitalisation of $ 10 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Quoin Pharmaceuticals Ltd (QNRX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.96
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.